I don't have that number at my fingertips, and it is hard to separate the cost of each component of the pharmaceutical system. The other complication in trying to do that sort of analysis is that the system has changed substantially since prior to the CDR. We've found an ever-increasing number and complexity of drugs, and at least in British Columbia, we have tried to use some of the resources that have been made available through the work being done by the common drug review for other initiatives within the province. So as we move forward, we have been looking at the issue of new indications for the old drugs and paying more attention to that. We've been enhancing our drug consideration for drug classes and those sorts of initiatives that we were not resourced for in the past.
So we don't have a clean number that I can provide you with at this point.